Zura Bio Limited

What they do

Zura Bio develops antibody medicines for autoimmune and inflammatory diseases with unmet need, working from human translational data including biomarkers and genetic associations. It has in-licensed three clinical-stage candidates: tibulizumab (ZB-106), a bispecific antibody neutralizing IL-17A and BAFF; crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7Rα; and torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33. Tibulizumab is the lead asset, running in two global Phase 2 trials for hidradenitis suppurativa (TibuSHIELD) and diffuse cutaneous systemic sclerosis (TibuSURE). The company has not completed any Phase 2 or Phase 3 trial and has no products approved for commercial sale.

Revenue drivers

• Tibulizumab (ZB-106) — Lead product candidate and the sole source of any future revenue; no commercial sales today. Two global Phase 2 trials are fully enrolled, with topline in Q4 2026 for HS and H1 2027 for SSc, and a third Phase 2 in polymyalgia rheumatica planned by year-end 2026.
• Crebankitug (ZB-168) — Fully human IgG1 antibody targeting IL-7Rα; evaluated in earlier third-party trials before in-licensing. The company is assessing future development strategies rather than running company-sponsored trials, so it is not currently a near-term revenue contributor.
• Torudokimab (ZB-880) — Fully human IgG4 antibody neutralizing IL-33, previously studied by third parties before in-licensing. Management is monitoring the IL-33 pathway and evaluating possible future development opportunities; no active company-sponsored program is described.
• Current revenue base — None. The company reports operating losses and no product sales, and states it has no products approved for commercial sale.

Recent performance

Second quarter 2026 net loss was $26.3 million, with R&D expense of $20.7 million versus $8.7 million in the prior-year period, driven by the Phase 2 tibulizumab programs. G&A expense fell to $8.6 million from $9.4 million, mainly on lower professional fees. Full-year net loss widened to $68.7 million in 2025 from $52.4 million in 2024, while operating cash use grew to $64.8 million from $28.1 million. As of June 30, 2026, the company held $205.1 million in cash and cash equivalents against $16.3 million of total liabilities and $197.1 million of shareholder equity.

Strategy

Zura Bio's stated strategy is to advance antibody candidates in immune-mediated diseases where translational and clinical evidence supports the targeted pathways. The company is prioritizing tibulizumab, having completed enrollment in both Phase 2 studies ahead of target, with 247 participants in TibuSHIELD and 91 in TibuSURE. It selected polymyalgia rheumatica as a third indication after FDA feedback it described as constructive and supportive, and plans to start the NEXUS-PMR Phase 2 study by year-end 2026. For crebankitug and torudokimab, the company continues to evaluate development and strategic options informed by translational evidence and the competitive landscape. It relies on third-party CDMOs and CROs for manufacturing and trial execution.

Risks

• No approved product or revenue — The company has no products approved for commercial sale, has not completed any Phase 2 or Phase 3 trial, and has incurred significant losses since inception in January 2022.
• Substantial additional capital required — Management states it will need substantial additional capital, and failure to raise it when needed or on acceptable terms could force delays, reductions or elimination of one or more development programs.
• Dependence on third parties — Zura relies on contract development manufacturing organizations for clinical materials and on contract research organizations, clinical trial sites and other third parties to conduct its trials.
• Clinical and regulatory timing uncertainty — The company cautions that timing of key events, study initiations and release of clinical data may take longer than anticipated or may not be achieved at all, and it may be unable to obtain regulatory approval.

Outlook

Management expects topline tibulizumab data from TibuSHIELD in hidradenitis suppurativa in the fourth quarter of 2026 and from TibuSURE in systemic sclerosis in the first half of 2027. It plans to initiate the NEXUS-PMR Phase 2 study in polymyalgia rheumatica by the end of 2026. The company states that existing cash and cash equivalents of $205.1 million as of June 30, 2026 should fund planned operations through at least the end of 2028.